USANA Health Sciences, Inc. (NYSE:USNA) Director John Turman Fleming Sells 1,000 Shares of Stock

USANA Health Sciences, Inc. (NYSE:USNA) Director John Turman Fleming sold 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $44.43, for a total transaction of $44,430.00. Following the sale, the director now owns 2,503 shares of the company’s stock, valued at $111,208.29. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

USANA Health Sciences Trading Down 2.9 %

Shares of NYSE USNA opened at $43.32 on Friday. The firm has a 50 day moving average of $45.71 and a 200 day moving average of $46.81. The firm has a market capitalization of $825.25 million, a price-to-earnings ratio of 13.50, a price-to-earnings-growth ratio of 1.49 and a beta of 0.90. USANA Health Sciences, Inc. has a 12-month low of $40.51 and a 12-month high of $67.32.

USANA Health Sciences (NYSE:USNA) last posted its quarterly earnings results on Tuesday, July 23rd. The company reported $0.54 earnings per share for the quarter, missing analysts’ consensus estimates of $0.65 by ($0.11). The firm had revenue of $212.87 million during the quarter, compared to the consensus estimate of $218.64 million. USANA Health Sciences had a return on equity of 11.13% and a net margin of 6.29%. During the same quarter in the previous year, the company earned $0.89 earnings per share. Sell-side analysts predict that USANA Health Sciences, Inc. will post 2.5 EPS for the current year.

Hedge Funds Weigh In On USANA Health Sciences

A number of hedge funds have recently modified their holdings of the company. CWM LLC boosted its position in shares of USANA Health Sciences by 21.8% in the first quarter. CWM LLC now owns 1,543 shares of the company’s stock worth $75,000 after purchasing an additional 276 shares during the period. New York State Common Retirement Fund lifted its holdings in shares of USANA Health Sciences by 1.2% in the fourth quarter. New York State Common Retirement Fund now owns 24,500 shares of the company’s stock worth $1,313,000 after buying an additional 279 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in shares of USANA Health Sciences by 9.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 5,849 shares of the company’s stock worth $284,000 after buying an additional 494 shares in the last quarter. Strs Ohio lifted its holdings in shares of USANA Health Sciences by 9.2% in the fourth quarter. Strs Ohio now owns 11,900 shares of the company’s stock worth $637,000 after buying an additional 1,000 shares in the last quarter. Finally, Quest Partners LLC purchased a new position in shares of USANA Health Sciences in the fourth quarter worth $66,000. 54.25% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the stock. StockNews.com lowered shares of USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 24th. DA Davidson cut their target price on shares of USANA Health Sciences from $46.00 to $38.00 and set a “neutral” rating for the company in a research report on Thursday, July 25th.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.